# US 2019/0376030 A1 · Regulatory t cell populations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376030 A1
- Document ID: US20190376030A1
- Status: Published application
- Kind: A1
- Application number: 16/433,251
- Filed: 2019-06-06
- Published: 2019-12-12
- Earliest claimed: 2018-06-06
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Alexander Y. Rudensky; Andrew G. Levine
- Web page: https://patentgrep.com/patent/US20190376030A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- C07K 14/47: from mammals
- C12N 2501/2327: Interleukin-27 (IL-27)
- C12N 2501/24: Interferons [IFN]
- C12N 2501/60: Transcription factors
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides regulatory T cells and regulatory T cell populations engineered to express a transcription factor. The present disclosure provides for treatment of immune disorders with regulatory T cells and regulatory T cell populations engineered to express a transcription factor.

## Claims

### Claim 1

An isolated population of regulatory T (Treg) cells which have been engineered to express Tbet.

### Claim 2 (depends on 1)

The population of claim 1, characterized by 2, 5, 10, 20, 30, 40, 50, 60 fold greater expression of Tbet relative to a reference.

### Claim 3 (depends on 1)

The population of claim 1, characterized by an ability to suppress an immune response when contacted with a system undergoing or at risk of the immune response.

### Claim 4 (depends on 3)

The population of claim 3, wherein the immune response is a Th1 type immune response.

### Claim 5 (depends on 4)

The population of claim 4, wherein suppression of a TH1 type immune response comprises reduced expression of IFNγ or IL-2 in the system.

### Claim 6 (depends on 1)

The population of claim 1, wherein 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20% of the Treg population expresses Tbet.

### Claim 7

A method of suppressing a TH1 type immune response the method comprising administering to a subject a population of Tregs which have been engineered to express Tbet.

### Claim 8 (depends on 7)

The method of claim 7, further comprising obtaining Tregs.

### Claim 9 (depends on 8)

The method of claim 8, wherein the Tregs are obtained from the subject.

### Claim 10 (depends on 8)

The method of claim 8, wherein the Tregs are obtained from an individual other than the subject

### Claim 11 (depends on 7)

The method of claim 7, wherein engineering comprises increasing expression of Tbet in the obtained Tregs.

### Claim 12 (depends on 11)

The method of claim 11, wherein increased expression of Tbet comprises stimulation of the obtained Tregs in the presence of IFNγ and IL-27.

### Claim 13 (depends on 11)

The method of claim 11, wherein engineering comprises introducing a vector expressing Tbet in to the obtained Tregs.

### Claim 14 (depends on 13)

The method of claim 13, wherein the vector is a viral vector.

### Claim 15 (depends on 7)

The method of claim 7, wherein engineering comprises increasing expression of Tbet through transfection of the obtained Tregs with a nucleic acid or amino acid sequence encoding Tbet.

### Claim 16

A method of preparing an specialized Treg population, the method comprising:
obtaining an initial Treg cell or population
culturing the initial Treg cell or population for a period of time and under conditions sufficient that a specialized Treg population characterized in that Tbet expression is increased 2, 5, 10, 20, 30, 40, 50, 60 fold relative to a reference is prepared.

### Claim 17 (depends on 16)

The method of claim 16, wherein the initial Treg cell or population has been engineered to express Tbet.

### Claim 18 (depends on 17)

The method of claim 17, wherein the engineering comprises stimulation of the obtained Tregs in the presence of IFNγ and IL-27.

### Claim 19 (depends on 17)

The method of claim 17, wherein the engineering comprises introducing a vector expressing Tbet in to the obtained Tregs.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vector is a viral vector.

### Claim 21 (depends on 17)

The method of claim 17, wherein the engineering comprises transfection of the obtained Tregs with a nucleic acid or amino acid sequence encoding Tbet.

### Claim 22 (depends on 16)

The method of claim 16, wherein the initial Treg cell or population is isolated from a subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the subject is a human subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the subject is suffering from or susceptible to a disease disorder or condition characterized by inflammation or autoimmunity.

### Claim 25 (depends on 24)

The method of claim 24, wherein the subject is suffering from or susceptible to a disease disorder or condition characterized by a Th1 immune response.

### Claim 26 (depends on 16)

The method of claim 16 further comprising steps of:
isolating the specialized Treg population; or
combining the specialized Treg population with a pharmaceutically acceptable carrier or excipient so that a pharmaceutical composition comprising the specialized Treg population is manufactured.
